Oncolytic Vaccinia Virus Harboring Aphrocallistes vastus Lectin Inhibits the Growth of Cervical Cancer Cells Hela S3

Mar Drugs. 2021 Sep 23;19(10):532. doi: 10.3390/md19100532.

Abstract

Aphrocallistes vastus lectin (AVL) is a C-type marine lectin produced by sponges. Our previous study demonstrated that genes encoding AVL enhanced the cytotoxic effect of oncolytic vaccinia virus (oncoVV) in a variety of cancer cells. In this study, the inhibitory effect of oncoVV-AVL on Hela S3 cervical cancer cells, a cell line with spheroidizing ability, was explored. The results showed that oncoVV-AVL could inhibit Hela S3 cells growth both in vivo and in vitro. Further investigation revealed that AVL increased the virus replication, promote the expression of OASL protein and stimulated the activation of Raf in Hela S3 cells. This study may provide insight into a novel way for the utilization of lection AVL.

Keywords: Aphrocallistes vastus lectin; Hela S3 cell line; oncolytic vaccinia virus; sphere formation assay.

MeSH terms

  • Adenine / analogs & derivatives*
  • Adenine / chemistry
  • Adenine / pharmacology
  • Adenine / therapeutic use
  • Animals
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Aquatic Organisms
  • Cell Proliferation / drug effects
  • Female
  • HeLa Cells / drug effects
  • Humans
  • Lectins / chemistry
  • Lectins / pharmacology*
  • Lectins / therapeutic use
  • Oncolytic Viruses / pathogenicity*
  • Porifera*
  • Tyramine / analogs & derivatives*
  • Tyramine / chemistry
  • Tyramine / pharmacology
  • Tyramine / therapeutic use
  • Uterine Cervical Neoplasms / drug therapy
  • Vaccinia virus / pathogenicity*

Substances

  • Antineoplastic Agents
  • Lectins
  • aphrocallistin
  • Adenine
  • Tyramine